Pfizer Operating Margin from 2010 to 2026

PFE Stock  EUR 23.27  0.24  1.04%   
Pfizer's Operating Profit Margin is decreasing over the last several years with slightly volatile swings. Operating Profit Margin is predicted to flatten to 0.21.
Check Pfizer financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pfizer's main balance sheet or income statement drivers, such as Discontinued Operations of 6.6 M, Interest Expense of 3.7 B or Selling General Administrative of 11.2 B, as well as many indicators such as Price To Sales Ratio of 2.16, Dividend Yield of 0.0727 or PTB Ratio of 1.85. Pfizer financial statements analysis is a perfect complement when working with Pfizer Valuation or Volatility modules.
  
This module can also supplement various Pfizer Technical models . Check out the analysis of Pfizer Correlation against competitors.
The Operating Margin trend for Pfizer Inc offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Pfizer is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.

Latest Pfizer's Operating Margin Growth Pattern

Below is the plot of the Operating Profit Margin of Pfizer Inc over the last few years. It is Pfizer's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pfizer's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.25 %10 Years Trend
Slightly volatile
   Operating Profit Margin   
       Timeline  

Pfizer Operating Margin Regression Statistics

Arithmetic Mean0.26
Geometric Mean0.25
Coefficient Of Variation24.92
Mean Deviation0.05
Median0.27
Standard Deviation0.06
Sample Variance0
Range0.2854
R-Value(0.33)
Mean Square Error0
R-Squared0.11
Significance0.20
Slope(0)
Total Sum of Squares0.07

Pfizer Operating Margin History

2026 0.21
2023 0.0889
2022 0.37
2021 0.26
2019 0.18
2015 0.27
2014 0.28

About Pfizer Financial Statements

Pfizer stakeholders use historical fundamental indicators, such as Pfizer's Operating Margin, to determine how well the company is positioned to perform in the future. Although Pfizer investors may analyze each financial statement separately, they are all interrelated. For example, changes in Pfizer's assets and liabilities are reflected in the revenues and expenses on Pfizer's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Pfizer Inc. Please read more on our technical analysis and fundamental analysis pages.
Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. PFIZER INC operates under Drug Manufacturers - Major classification in Germany and is traded on Frankfurt Stock Exchange. It employs 92400 people.

Currently Active Assets on Macroaxis

When determining whether Pfizer Inc is a strong investment it is important to analyze Pfizer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pfizer's future performance. For an informed investment choice regarding Pfizer Stock, refer to the following important reports:
Check out the analysis of Pfizer Correlation against competitors.
You can also try the CEOs Directory module to screen CEOs from public companies around the world.
It's important to distinguish between Pfizer's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pfizer should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Pfizer's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.